Canine Epilepsy: Advanced Welfare Management

Key Welfare Considerations

• Idiopathic epilepsy affects approximately 0.5-5% of the dog population with significant welfare implications.
• Seizures cause acute welfare impacts including loss of consciousness, involuntary muscle activity, and post-ictal distress.
• Post-ictal phase can last hours — disorientation, blindness, and anxiety welfare impacts require calm, safe management.
• Status epilepticus (seizures lasting over 5 minutes) is a life-threatening welfare emergency requiring immediate treatment.
• Phenobarbitone remains a first-line antiepileptic drug with established welfare efficacy in dogs.
• Potassium bromide is used as adjunctive therapy — welfare monitoring includes sedation and ataxia assessment.
• Imepitoin is a newer option with fewer sedative welfare side effects for idiopathic epilepsy.
• Regular blood level monitoring ensures therapeutic efficacy while minimising drug toxicity welfare impacts.
• Seizure diaries provide welfare trend data — increased frequency indicates need for treatment review.
• Rescue medication (midazolam or diazepam) enables home management of prolonged seizures for welfare.
• Cognitive function may decline with frequent seizures — welfare monitoring should include behaviour assessment.
• Anxiety and fear are common interictal welfare concerns requiring targeted behavioural management.
• Drug interactions with commonly used veterinary medicines require careful welfare consideration.
• Owner anxiety about managing epilepsy significantly affects the welfare experience of both dog and owner.
• Quality of life assessment in epileptic dogs should address both seizure burden and interictal welfare.